Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$125.01 USD
-0.68 (-0.54%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $125.10 +0.09 (0.07%) 5:06 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SRPT 125.01 -0.68(-0.54%)
Will SRPT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRPT
Why Is Sarepta Therapeutics (SRPT) Down 1.9% Since Last Earnings Report?
Dyne Reports Mixed Data From DMD Study, Key Executives Step Down
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -10.33% in 4 Weeks, Here's Why You Should You Buy the Dip in Sarepta Therapeutics (SRPT)
Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics
Other News for SRPT
10 Health Care Stocks With Whale Alerts In Today's Session
Sarepta management to meet with Cantor Fitzgerald
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
Sarepta Therapeutics Expands Board, Welcomes New Director
SRPT Makes Notable Cross Below Critical Moving Average